• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嗜酸性粒细胞减少作为慢性阻塞性肺疾病急性加重期无创通气使用的预后生物标志物

Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations.

作者信息

Bartziokas Konstantinos, Papathanasiou Evgenia, Papaioannou Andriana I, Papanikolaou Ilias, Antonakis Emmanouil, Makou Ioanna, Hillas Georgios, Karampitsakos Theodoros, Papaioannou Ourania, Dimakou Katerina, Apollonatou Vasiliki, Verykokou Galateia, Papiris Spyros, Bakakos Petros, Loukides Stelios, Kostikas Konstantinos

机构信息

Respiratory Medicine Department, University of Ioannina, 45110 Ioannina, Greece.

2nd Respiratory Medicine Department, National and Kapodistrian University of Athens, 10679 Athens, Greece.

出版信息

J Pers Med. 2023 Apr 19;13(4):686. doi: 10.3390/jpm13040686.

DOI:10.3390/jpm13040686
PMID:37109072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10145416/
Abstract

BACKGROUND

In recent years, blood eosinophils have been evaluated as a surrogate biomarker for eosinophilic airway inflammation and as a prognostic indicator of the outcomes of hospitalized COPD subjects. During an exacerbation of COPD, eosinopenia has been proposed as a prognostic marker of adverse outcomes.

OBJECTIVES

The aim of the present post hoc analysis was to elucidate the effectiveness of blood eosinophils for predicting the need of NIV in subjects with COPD exacerbation.

METHODS

Consecutive subjects admitted to a hospital for COPD exacerbation were included in the analysis. The eosinophil count from the first complete blood count was used to designate the eosinophil groups. The relationship between the clinical characteristics and blood eosinophil counts, as dichotomized using 150 cells/μL, was evaluated. Results Subjects with blood eosinophil number < 150 k/μL had a more severe disease on admission compared to subjects with ≥150 k/μL, regarding pH 7.400 (7.36, 7.44) vs. 7.42 (7.38, 7.45), = 0.008, PO/FiO levels 238.1 (189.8, 278.6) vs. 276.2 (238.2, 305.6), < 0.001, CRP (mg/L) levels 7.3 (3.1, 19.9) vs. 3.5 (0.7, 7.8), < 0.001 and required a longer hospital stay (days) 10.0 (8.0, 14.0) vs. 5.0 (3.0, 7.0) < 0.001 respectively. The number of blood eosinophils correlated with the levels of CRP upon admission ( < 0.001, r = -0.334), with arterial pH upon admission ( < 0.030, r = 0.121), with PO/FiO ( < 0.001, r = -0.248), and with duration of hospital stay ( < 0.001, r = -0.589). In the multinomial logistic regression analysis, blood eosinophil count < 150 k/μL was an independent predictor of the use of NIV during hospital stay.

CONCLUSION

During COPD exacerbation, low blood eosinophil levels upon admission are related to more severe disease and can be used as a predictor of the need of NIV. Further prospective studies are needed to identify the use of blood eosinophil levels as a predictor of unfavorable outcomes.

摘要

背景

近年来,血液嗜酸性粒细胞已被评估为嗜酸性气道炎症的替代生物标志物以及住院慢性阻塞性肺疾病(COPD)患者预后的指标。在COPD急性加重期,嗜酸性粒细胞减少被认为是不良预后的预测指标。

目的

本事后分析的目的是阐明血液嗜酸性粒细胞对预测COPD急性加重患者无创通气(NIV)需求的有效性。

方法

纳入因COPD急性加重连续入院的患者进行分析。首次全血细胞计数中的嗜酸性粒细胞计数用于划分嗜酸性粒细胞组。评估临床特征与以150个细胞/μL进行二分的血液嗜酸性粒细胞计数之间的关系。结果血液嗜酸性粒细胞数<150 k/μL的患者入院时病情比≥150 k/μL的患者更严重,pH值分别为7.400(7.36,7.44)vs. 7.42(7.38,7.45),P = 0.008;动脉血氧分压/吸入氧分数(PO/FiO)水平分别为238.1(189.8,278.6)vs. 276.2(238.2,305.6),P<0.001;C反应蛋白(CRP)(mg/L)水平分别为7.3(3.1, 19.9)vs. 3.5(0.7, 7.8),P<0.001,且住院时间更长(天数)分别为10.0(8.0, 14.0)vs. 5.0(3.0, 7.0),P<0.001。血液嗜酸性粒细胞数量与入院时CRP水平相关(P<0.001,r = -0.334),与入院时动脉pH值相关(P<0.030,r = 0.121),与PO/FiO相关(P<0.001,r = -0.248),与住院时间相关(P<0.001,r = -0.589)。在多项逻辑回归分析中,血液嗜酸性粒细胞计数<150 k/μL是住院期间使用NIV的独立预测因素。

结论

在COPD急性加重期,入院时血液嗜酸性粒细胞水平低与病情更严重相关,可作为NIV需求的预测指标。需要进一步的前瞻性研究来确定血液嗜酸性粒细胞水平作为不良预后预测指标的用途。

相似文献

1
Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations.嗜酸性粒细胞减少作为慢性阻塞性肺疾病急性加重期无创通气使用的预后生物标志物
J Pers Med. 2023 Apr 19;13(4):686. doi: 10.3390/jpm13040686.
2
Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.血液嗜酸性粒细胞作为未来 COPD 加重风险的生物标志物:来自 11 项临床试验的汇总数据。
Respir Res. 2020 Sep 17;21(1):240. doi: 10.1186/s12931-020-01482-1.
3
High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients - a retrospective analysis.高嗜酸性粒细胞计数与 COPD 加重患者的住院时间缩短相关 - 一项回顾性分析。
Respir Res. 2020 May 6;21(1):106. doi: 10.1186/s12931-020-01365-5.
4
Admission blood eosinophil count, inpatient death and death at 1 year in exacerbating patients with COPD.慢性阻塞性肺疾病(COPD)急性加重患者的入院血嗜酸性粒细胞计数、住院死亡及1年死亡率
Thorax. 2023 Nov;78(11):1090-1096. doi: 10.1136/thorax-2022-219463. Epub 2023 Jul 24.
5
Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.血液嗜酸性粒细胞计数,在后 RCT 和观察性研究中预测吸入性皮质类固醇预防 COPD 加重的有效性标志物:系统评价和荟萃分析。
Respir Res. 2020 Jan 3;21(1):3. doi: 10.1186/s12931-019-1268-7.
6
Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD.血液嗜酸性粒细胞与 COPD 严重住院加重期的结局。
Chest. 2016 Aug;150(2):320-8. doi: 10.1016/j.chest.2016.01.026. Epub 2016 Feb 3.
7
The association between eosinophilic exacerbation and eosinophilic levels in stable COPD.稳定期 COPD 中嗜酸性粒细胞恶化与嗜酸性粒细胞水平的关系。
BMC Pulm Med. 2021 Mar 2;21(1):74. doi: 10.1186/s12890-021-01443-4.
8
Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.评估英国和美国 COPD 人群的恶化和血嗜酸性粒细胞。
Respir Res. 2019 Aug 7;20(1):178. doi: 10.1186/s12931-019-1130-y.
9
Anti-IL-5 therapies for chronic obstructive pulmonary disease.抗白细胞介素-5 疗法治疗慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD013432. doi: 10.1002/14651858.CD013432.pub2.
10
Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations.血嗜酸性粒细胞计数可预测 COPD 加重的住院时间。
Respirology. 2020 Mar;25(3):259-266. doi: 10.1111/resp.13660. Epub 2019 Aug 6.

引用本文的文献

1
Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far?嗜酸性慢性阻塞性肺疾病。我们目前了解到了什么?
Pulm Ther. 2025 Mar;11(1):7-24. doi: 10.1007/s41030-024-00280-0. Epub 2024 Dec 11.
2
A Low Eosinophil to Platelet Ratio as a Worse Prognostic Index for Emergency Department Attendance in Acute Exacerbation of COPD.低嗜酸性粒细胞与血小板比值可作为 COPD 急性加重急诊就诊患者预后不良的预测指标。
Int J Chron Obstruct Pulmon Dis. 2024 Jan 16;19:139-147. doi: 10.2147/COPD.S442715. eCollection 2024.
3
Using complete blood count, serum immunoglobulins G/A/M and complement C3/C4 levels to predict the risk of COPD acute exacerbation: 2-year follow-up in a single-center prospective cohort study.应用全血细胞计数、血清免疫球蛋白 G/A/M 及补体 C3/C4 水平预测 COPD 急性加重风险的研究:单中心前瞻性队列研究 2 年随访结果
Clin Exp Med. 2023 Dec;23(8):5161-5176. doi: 10.1007/s10238-023-01117-x. Epub 2023 Jun 16.

本文引用的文献

1
Low Eosinophil Phenotype Predicts Noninvasive Mechanical Ventilation Use in Patients with Hospitalized Exacerbations of COPD.低嗜酸性粒细胞表型可预测慢性阻塞性肺疾病急性加重期住院患者无创机械通气的使用情况。
J Inflamm Res. 2022 Feb 24;15:1259-1271. doi: 10.2147/JIR.S343918. eCollection 2022.
2
Blood eosinophils as predictor of outcomes in patients hospitalized for COPD exacerbations: a prospective observational study.血液嗜酸性粒细胞作为 COPD 加重住院患者结局的预测因子:一项前瞻性观察研究。
Biomarkers. 2021 Jun;26(4):354-362. doi: 10.1080/1354750X.2021.1903998. Epub 2021 Apr 11.
3
DECAF score as a mortality predictor for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis.DECAF 评分作为慢性阻塞性肺疾病急性加重死亡率的预测指标:系统评价和荟萃分析。
BMJ Open. 2020 Oct 30;10(10):e037923. doi: 10.1136/bmjopen-2020-037923.
4
Low and High Blood Eosinophil Counts as Biomarkers in Hospitalized Acute Exacerbations of COPD.低和高血嗜酸性粒细胞计数作为 COPD 急性加重住院患者的生物标志物。
Chest. 2019 Jul;156(1):92-100. doi: 10.1016/j.chest.2019.02.406. Epub 2019 Apr 9.
5
Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure.ERS/ATS 官方临床实践指南:急性呼吸衰竭的无创通气。
Eur Respir J. 2017 Aug 31;50(2). doi: 10.1183/13993003.02426-2016. Print 2017 Aug.
6
Analysis of factors influenced by the effectiveness of non-invasive ventilation in the treatment of acute exacerbation of chronic obstructive pulmonary disease with different severities.不同严重程度慢性阻塞性肺疾病急性加重期无创通气治疗效果的影响因素分析
Eur Rev Med Pharmacol Sci. 2016 Nov;20(22):4775-4781.
7
Acute exacerbation of COPD: is it the "stroke of the lungs"?慢性阻塞性肺疾病急性加重:它是“肺部的中风”吗?
Int J Chron Obstruct Pulmon Dis. 2016 Jul 13;11:1579-86. doi: 10.2147/COPD.S106160. eCollection 2016.
8
Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD.血液嗜酸性粒细胞与 COPD 严重住院加重期的结局。
Chest. 2016 Aug;150(2):320-8. doi: 10.1016/j.chest.2016.01.026. Epub 2016 Feb 3.
9
Bacterial infection, airway and systemic inflammation and clinical outcomes before and after treatment of AECOPD, a longitudinal and cross-sectional study.细菌感染、气道与全身炎症以及慢性阻塞性肺疾病急性加重期治疗前后的临床结局:一项纵向和横断面研究
COPD. 2015 Feb;12(1):19-30. doi: 10.3109/15412555.2014.898043. Epub 2014 May 6.
10
The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease.DECAF 评分:预测慢性阻塞性肺疾病加重期的住院死亡率。
Thorax. 2012 Nov;67(11):970-6. doi: 10.1136/thoraxjnl-2012-202103. Epub 2012 Aug 15.